

May 2, 2018

To,

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,


Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2018.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head - Legal & Company Secretary



Encl: As above



RPG Life Sciences revenue from operations grows by 17 % and Profit Before Tax by 40%

Mumbai, 2 May, 2018: RPG Life Sciences Limited has announced its audited financial results for the quarter and year ended March 31st, 2018.

Full Year Highlights	YoY Net Revenue from Operations (excluding excise duties)	YoY PBT from Operations
	Rs 343.94 crores – up from Rs 293.64 crores	Rs 20.36 crores – up from Rs 14.54 crores

Q4 FY18 Highlights	YoY Net Revenue from Operations (excluding excise duty)	YoY PBT from Operations
	Rs 83.46 crores – up from Rs 71.02 crores	Rs 4.39 crores – up from Rs 1.26 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a robust increase in revenue Y-O-Y for full year at Rs. 343.94 crores which is a 17% increase as against Rs. 293.64 crores posted last year. The company's PBT stood at Rs 20.36 crores as against Rs.14.54 crores which marks a substantial 40% jump.

The revenue for Q4FY 18 at Rs 83.46 crores grew by 17.5 % and the company's PBT from operations grew by a whopping 352 % over Q4FY17.

"We are growing consistently for past 3 years. Now the time has come to consolidate our position by increasing investments in new product development, upgradation of quality systems and productivity improvement. In addition to current priorities to sustain our growth we will focus on US readiness. In domestic market we will continue to focus on existing therapies and broaden the product range through introduction of brand extensions." said Mr. C.T. Renganathan, Managing Director, RPG Life Sciences Ltd.

FY18 Other Highlights	1. EDITDA margins improved from 9.2% to 11.2%
	2. Domestic formulation net sales grew by 17%
	3. Global Generic business net sales grew by 53%
	4. API net sales grew by 21%

Q4 FY18 Other Highlights	1. EDITDA margins improved from 7.6% to 10.7%
	2. Domestic formulation new sales grew by 10%
	3. Global Generic business net sales grew by 51%
	4. API net sales grew by 16%

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

Mumbai head-quartered RPG Enterprises is one of India's largest industrial conglomerates. With over 15 companies in its fold, the group has a strong presence across core business sectors such as Infrastructure, Tyre, IT and Specialty. Established in 1979, RPG Enterprises is one of India's fastest growing business groups with a turnover in excess of Rs 21,000 crore.

Media Contact:

Sumeet Chatterjee

Senior Vice President – Group Communications

sumeet@rpg.in

+91 9820340650

